Skip to main content
. 2021 Jan 26;87(8):3206–3217. doi: 10.1111/bcp.14736

FIGURE 6.

FIGURE 6

Circulating concentration of (A, B) alanine transaminase (ALT; IU/L), (C, D) microRNA (miR)‐122 (fM) and (E, F) K18 (U/L) over the course of treatment (weeks) for 2 cases who developed DILI as predefined as >3× upper limit of normal ALT in the presence of symptoms or >5× upper limit of normal in absence of symptoms. 8 Case 1 (A, C, E); Case 2 (B, D, F)